![](https://s3.amazonaws.com/cache.altmetric.com/policy/thumbnails/thumbnail-c50715e5b2e42ff49a1afa6ac2cbf15a3ccdad891425b6312259e3f87e34f5da.jpg)
Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details
Cited by Canadian Agency for Drugs and Technologies in Health on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.